Zura Bio (NASDAQ: ZURA) taps Kim Davis as interim CEO after leave

Rhea-AI Filing Summary

Zura Bio Limited reported a leadership change triggered by a medical leave. On October 8, 2025, Chief Executive Officer and Board member Robert Lisicki informed the company that he is taking a medical leave of absence effective October 10, 2025.

The Board appointed Kim Davis, currently Chief Operating Officer, Chief Legal Officer and Corporate Secretary, to serve as interim Chief Executive Officer and interim principal executive officer starting October 10, 2025, while she continues in her existing roles. The company notes that there are no special arrangements behind her appointment, no related-party transactions requiring disclosure, and no family relationships between Davis and any directors or executive officers.

Positive

• None.

Negative

• CEO medical leave and interim leadership change may create short-term uncertainty around executive leadership continuity.

Insights

Corporate governance analyst

CEO medical leave prompts interim appointment, raising short-term leadership continuity questions.

Zura Bio Limited disclosed that CEO and director Robert Lisicki will take a medical leave of absence effective October 10, 2025. In response, the Board appointed Kim Davis, already serving as Chief Operating Officer, Chief Legal Officer and Corporate Secretary, as interim Chief Executive Officer and interim principal executive officer starting the same date.

This structure concentrates multiple key roles in a single executive, which may test management bandwidth but also ensures continuity from an existing senior leader. The company specifies that Davis’s appointment is not based on any special arrangements, that there are no related-party transactions requiring disclosure under Item 404(a), and that she has no family relationships with current directors or executive officers, which supports governance transparency around the transition.

false 0001855644 0001855644 2025-10-08 2025-10-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Warrants [Member]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

October 8, 2025

Date of Report (Date of earliest event reported)

Zura Bio Limited

(Exact name of registrant as specified in its charter)

Cayman Islands		001-40598		98-1725736
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

 (Address of principal executive offices, including zip code)

(702) 825-9872

 (Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share		ZURA		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 8, 2025, Robert Lisicki, Chief Executive Officer (principal executive officer) and member of the Board of Directors of Zura Bio Limited (the “Company”) informed the Company that he is taking a medical leave of absence, effective October 10, 2025. Accordingly, effective October 10, 2025, the Company’s Board of Directors appointed Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary, to serve as the Company’s interim Chief Executive Officer and interim principal executive officer, in addition to her current duties.

Biographical and other information for Ms. Davis is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2025 and is incorporated herein by reference. Ms. Davis is not party to any arrangement or understanding pursuant to which she was appointed as an officer, nor is she party to any transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between Ms. Davis and any of the Company’s directors or executive officers.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZURA BIO LIMITED
Date: October 10, 2025	By:	/s/ Kim Davis
		Kim Davis
		Interim Chief Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary

FAQ

What leadership change did Zura Bio (ZURA) disclose in this 8-K?

Zura Bio reported that Chief Executive Officer and Board member Robert Lisicki will take a medical leave of absence effective October 10, 2025, prompting an interim leadership change.

Who is serving as interim CEO of Zura Bio (ZURA)?

Kim Davis, currently Chief Operating Officer, Chief Legal Officer and Corporate Secretary, was appointed to serve as interim Chief Executive Officer and interim principal executive officer effective October 10, 2025.

Does Kim Davis retain her other roles at Zura Bio while interim CEO?

Yes. Kim Davis will serve as interim CEO and interim principal executive officer in addition to continuing as Chief Operating Officer, Chief Legal Officer and Corporate Secretary.

Is Kim Davis’s interim CEO appointment based on any special arrangement?

The company states that Kim Davis is not party to any arrangement or understanding pursuant to which she was appointed as an officer.

Are there related-party transactions or family relationships involving Kim Davis at Zura Bio?

Zura Bio notes that Kim Davis is not party to any transactions requiring disclosure under Item 404(a) of Regulation S-K and that there are no family relationships between her and any directors or executive officers.

When did Zura Bio’s CEO Robert Lisicki notify the company about his medical leave?

Robert Lisicki informed Zura Bio of his decision to take a medical leave of absence on October 8, 2025.